Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study

Clin Exp Hypertens. 1997 Jul-Aug;19(5-6):843-55. doi: 10.3109/10641969709083190.

Abstract

Cerebrovascular disease and high blood pressure both appear to increase the risk of vascular dementia. PROGRESS aims to investigate whether blood pressure lowering with an angiotensin coverting enzyme inhibitor-based regimen will reduce the risk of cognitive impairment in patients with a history of stroke or transient ischaemic attack. A total of at least 6000 patients will be randomised to receive perindopril (+/- indapamide) or matching placebo(s), with treatment and follow-up scheduled to continue for at least 4 years. Substudies will investigate the effects of treatment on cognitive decline in subgroups defined by apo-E genotype and on white matter lesions assessed by magnetic resonance imaging. Final results from the study should be available in 2001.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Antihypertensive Agents / pharmacology*
  • Blood Pressure / drug effects*
  • Cerebrovascular Disorders / drug therapy*
  • Cerebrovascular Disorders / physiopathology
  • Cerebrovascular Disorders / psychology
  • Clinical Protocols
  • Dementia, Vascular / physiopathology
  • Dementia, Vascular / prevention & control*
  • Diuretics / pharmacology
  • Female
  • Humans
  • Indapamide / pharmacology
  • Indoles / pharmacology*
  • Ischemic Attack, Transient / drug therapy
  • Ischemic Attack, Transient / physiopathology
  • Ischemic Attack, Transient / psychology
  • Male
  • Middle Aged
  • Perindopril

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Diuretics
  • Indoles
  • Indapamide
  • Perindopril